Pneumococcal vaccine Formulation 3

BIOLOGICAL2 trials

Sponsors

Sanofi, Sanofi Pasteur, a Sanofi Company

Conditions

Pneumococcal InfectionsPneumococcal PneumoniaStreptococcus Pneumoniae Infections

Phase 1

Study of Two Investigational Pneumococcal Vaccines in Healthy Adults

CompletedNCT01444339

SanofiPneumococcal Infections, Pneumococcal Pneumonia, Streptococcus Pneumoniae Infections

Start: 2010-02-28End: 2010-09-30Updated: 2011-09-30

Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults

CompletedNCT01444352

Sanofi Pasteur, a Sanofi CompanyPneumococcal Infections, Pneumococcal Pneumonia, Streptococcus Pneumoniae Infections

Start: 2010-06-30End: 2011-01-31Updated: 2015-03-18

Related Papers

Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.

2012-11-1273 citations

Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.

2012-11-0262 citations